BioLineRx Ltd. (BLRX)

IL — Healthcare Sector
Peers: ARDX  LXRX  MCRB  IBRX  XFOR  MREO  INZY  TERN  LPTX  VRCA  VRNA  GRTX  ARQT  PLX  CDTX  FBIO  MBIO  ACHL  APTO  FBIOP 

Automate Your Wheel Strategy on BLRX

With Tiblio's Option Bot, you can configure your own wheel strategy including BLRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BLRX
  • Rev/Share 0.0242
  • Book/Share 0.0112
  • PB 24.3229
  • Debt/Equity 1.1173
  • CurrentRatio 1.7593
  • ROIC -1.1369

 

  • MktCap 15256100.0
  • FreeCF/Share -0.0367
  • PFCF -0.3473
  • PE -35.5071
  • Debt/Assets 0.3866
  • DivYield 0
  • ROE -0.7526

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Why Is Nano-Cap BioLineRx Stock Surging On Friday?
BLRX
Published: May 30, 2025 by: Benzinga
Sentiment: Positive

BioLineRx Ltd's BLRX poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.

Read More
image for news Why Is Nano-Cap BioLineRx Stock Surging On Friday?
BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript
BLRX
Published: May 27, 2025 by: Seeking Alpha
Sentiment: Neutral

BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2025 Earnings Conference Call May 27, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Philip Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - H.C.

Read More
image for news BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript
BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript
BLRX
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Neutral

BioLineRx Ltd. (NASDAQ:BLRX ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Irina Koffler - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants Joe Pantginis - HC Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.

Read More
image for news BioLineRx Ltd. (BLRX) Q4 2024 Earnings Call Transcript
BioLineRx to Report 2024 Annual Results on March 31, 2025
BLRX
Published: March 24, 2025 by: PRNewsWire
Sentiment: Neutral

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , March 24, 2025 /PRNewswire/ -- BioLineRx Ltd.

Read More
image for news BioLineRx to Report 2024 Annual Results on March 31, 2025

About BioLineRx Ltd. (BLRX)

  • IPO Date 2011-07-27
  • Website https://www.biolinerx.com
  • Industry Biotechnology
  • CEO Mr. Philip A. Serlin CPA, CPA, M.B.A., MBA
  • Employees 28

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.